BioSeek

NEW YORK (GenomeWeb News) – DiscoveRx today said that it has acquired BioSeek, maker of the BioMAP platform of cell-based disease models for drug screening.
Financial terms of the deal were not disclosed.

NEW YORK (GenomeWeb News) – BioSeek today said that the US Environmental Protection Agency has extended the firm's contract to participate in the ToxCast screening program.

A research team led by scientists at proteomics firm Cellzome has developed a selective inhibitor to the PI3 kinase isoform PI3Kγ.

Cellzome will use the BioMap platform in its inflammatory disease drug discovery projects.

BioSeek will apply its BioMap predictive human disease models to screen Amylin's library.

The Japanese pharmaceutical developer has licensed the BioMap platform for drug toxicology research projects.

BioSeek will use its BioMap system to conduct screening for Ono Pharmaceuticals in its compound studies.

The acquisition will combine Asterand's tissue-based services for drug discovery with BioSeek's BioMap platform and human cell-based assays.

The firm will profile compounds for the second phase of the EPA initiative.

Pages

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.